NN Investment Partners Holdings N.V. reduced its position in United Therapeutics Corporation (NASDAQ:UTHR) by 93.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,027 shares of the biotechnology company’s stock after selling 108,212 shares during the period. NN Investment Partners Holdings N.V.’s holdings in United Therapeutics Corporation were worth $952,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the company. First Trust Advisors LP raised its position in shares of United Therapeutics Corporation by 92.8% in the third quarter. First Trust Advisors LP now owns 480,971 shares of the biotechnology company’s stock worth $56,793,000 after buying an additional 231,502 shares during the period. Bridgewater Wealth & Financial Management LLC raised its position in United Therapeutics Corporation by 6.4% in the third quarter. Bridgewater Wealth & Financial Management LLC now owns 48,028 shares of the biotechnology company’s stock worth $5,671,000 after buying an additional 2,896 shares during the last quarter. Hikari Power Ltd bought a new position in United Therapeutics Corporation during the third quarter worth $2,846,000. South Texas Money Management Ltd. bought a new position in United Therapeutics Corporation during the third quarter worth $15,746,000. Finally, New Amsterdam Partners LLC NY raised its position in United Therapeutics Corporation by 9.8% in the third quarter. New Amsterdam Partners LLC NY now owns 46,408 shares of the biotechnology company’s stock worth $5,480,000 after buying an additional 4,139 shares during the last quarter.

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) traded down 0.43% during midday trading on Friday, reaching $129.92. The company had a trading volume of 578,775 shares. The firm’s 50 day moving average is $124.34 and its 200 day moving average is $138.37. United Therapeutics Corporation has a 1-year low of $97.52 and a 1-year high of $169.89. The stock has a market capitalization of $5.85 billion, a PE ratio of 9.12 and a beta of 1.56.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.12 by $0.77. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The company had revenue of $370.50 million during the quarter, compared to analysts’ expectations of $399.59 million. During the same period last year, the company posted $3.02 earnings per share. The firm’s quarterly revenue was up .4% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Corporation will post $14.42 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “NN Investment Partners Holdings N.V. Sells 108,212 Shares of United Therapeutics Corporation (UTHR)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/06/16/nn-investment-partners-holdings-n-v-has-952000-position-in-united-therapeutics-co-uthr-updated-updated.html.

A number of research firms have weighed in on UTHR. Jefferies Group LLC reiterated a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a research note on Thursday, June 8th. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. BidaskClub upgraded United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, June 9th. Zacks Investment Research lowered United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Monday, February 27th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research note on Monday, April 3rd. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. United Therapeutics Corporation presently has an average rating of “Hold” and an average price target of $137.09.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,265 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $119.40, for a total value of $151,041.00. Following the completion of the transaction, the chief executive officer now directly owns 1,405 shares of the company’s stock, valued at $167,757. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 1,240 shares of the firm’s stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $129.60, for a total transaction of $160,704.00. Following the transaction, the chief executive officer now directly owns 1,380 shares of the company’s stock, valued at $178,848. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,020 shares of company stock valued at $2,154,373. 7.50% of the stock is currently owned by corporate insiders.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.